Advertisement · 728 × 90
#
Hashtag
#Partneship
Advertisement · 728 × 90
Preview
Regeneron and Tessera ink $275 mil pact for gene editing therapy The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.

Regeneron Pharmaceuticals and Tessera Therapeutics sign a $275 million deal to develop TSRA-196, a potential one-time #GeneEditing therapy for Alpha-1 Antitrypsin Deficiency.

#News #deal #partneship #GeneTherapy #AATD #Pharma

0 0 0 0
Preview
Regeneron and Tessera ink $275 mil pact for gene editing therapy The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.

Regeneron Pharmaceuticals and Tessera Therapeutics sign a $275 million deal to develop TSRA-196, a potential one-time #GeneEditing therapy for Alpha-1 Antitrypsin Deficiency.

#News #deal #partneship #GeneTherapy #AATD #Pharma

0 0 0 0
Post image

Yankton Medical Clinic, P.C. is pleased to announce a new educational partnership with Southeast Technical College's Nursing program. Beginning this fall, the clinic will proudly serve as a clinical rotation site for Southeast Tech nursing students.

buff.ly/Ews3FAk

#MED #YMC #Partneship

0 0 0 0